Alignment Healthcare (ALHC) Drops -43% in 30 Days on Medicare Star Ratings Pressure
Key Takeaways
- Alignment Healthcare shares fell approximately 43% in the 30 days through October 9, 2026, sliding from a $13.03 close on September 9 to roughly $7.39.
- The decline was driven chiefly by a September 15 disclosure at Baird's Global Healthcare Conference and a subsequent CMS Medicare Advantage Star Ratings downgrade on the company's largest contract.
- The broader trend is even steeper, with shares down roughly 65% from about $21 per share in early July.
- Key pressures include rising medical costs, a lower 2027 Star Rating on the California H3815 HMO contract, analyst price-target cuts, and investor-rights investigations.
- Management has reaffirmed its guidance and characterized the issues as near-term "transformation noise" rather than a fundamental deterioration of the business.
Alignment Healthcare (ALHC) Business and Competitive Position
Alignment Healthcare, Inc. operates as a technology-enabled Medicare Advantage insurer serving eligible seniors. It pairs a proprietary data and analytics platform with a high-touch clinical care model that offers HMO, PPO, and special needs plans in California, Arizona, Nevada, North Carolina, and Texas. The approach emphasizes care coordination and population-health management to improve outcomes and manage medical costs. In the Medicare Advantage space it competes with larger players such as UnitedHealth and Humana. I track the stock because of its membership and revenue growth trajectory, progress toward profitability, and the importance of Star Ratings for bonus revenue.
ALHC Stock Performance Over the Past 30 Days and Quarter
From September 9 through October 9, 2026, ALHC moved from a $13.03 close to roughly $7.39, a decline of about 43%. The drop featured two sharp legs lower: one in mid-September and another in early October that took the shares to a new 52-week low. Looking back further, the stock traded near $21 in early July, so the loss over the past three months totals roughly 65% as several negative catalysts overlapped.
Drivers Behind the Recent 30-Day Move
The clearest near-term catalyst arrived on September 15, 2026, when management spoke at Baird's Global Healthcare Conference. Executives noted an additional $10 million to $11 million in planned second-half investments and highlighted medical-cost pressures from hospital billing practices, disputes, appeals, and skilled-nursing-facility trends. The stock fell roughly 20% over the next two sessions on elevated volume. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
In early October the Centers for Medicare & Medicaid Services released 2027 Star Ratings that lowered the California H3815 HMO contract from 4.0 to 3.5 stars. That contract accounts for more than 75% of membership, and most Medicare Advantage plans need at least 4 stars for bonus payments. The share of enrollment in 4-star-or-better plans fell from about 98% to roughly 24%. JPMorgan cut its price target to $10 from $22 while keeping an Overweight rating. Alignment has disputed the 3.5-star score and plans to pursue administrative remedies and litigation. Separately, law firms including Hagens Berman and Rosen opened investigations citing a whistleblower complaint about expense classification.
Quarterly Context and Broader Pressures
The larger quarterly decline reflects more than one headline. On July 30, 2026, second-quarter revenue missed expectations and guidance implied only about 30% of full-year adjusted EBITDA would come in the second half, sending shares down more than 20% the next day. That reaction was followed by the September conference disclosures and the October Star Ratings update, raising questions about medical-cost trends, reserve adequacy, and the path from growth to profitability. Sector-wide scrutiny on Stars, risk adjustment, and utilization added to the headwinds.
Key Items to Watch Going Forward
Investors will focus on the third-quarter earnings report for any updates to full-year guidance and signs that institutional and hospital cost pressures are moderating. The outcome of planned appeals and litigation over the Star Ratings methodology could affect future bonus revenue. Other areas to monitor include medical-cost trends across Medicare Advantage, the 2028 bid cycle and new-state expansion plans, reserve adequacy for 2025 and 2026 dates of service, and resolution of the pending investor-rights investigations. From what I see, regulatory changes around Stars and risk adjustment remain relevant for the whole sector.
Exploring Tickeron AI Trading Bots
In my own research I have found Tickeron’s AI Trading Bots helpful for testing different strategies across timeframes and market conditions. The platform offers hundreds of bots that trade thousands of tickers, with only the top-performing and most relevant ones featured for review. Traders can examine various approaches before deciding on a single method. For those who want to combine automated signals with their own analysis, the Trending AI Robots page provides a practical starting point.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
ALHC in upward trend: price may ascend as a result of having broken its lower Bollinger Band on September 15, 2026
ALHC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 34 of 39 cases where ALHC's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 87%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where ALHC's RSI Oscillator exited the oversold zone, 26 of 31 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 84%.
The Momentum Indicator moved above the 0 level on October 05, 2026. You may want to consider a long position or call options on ALHC as a result. In 54 of 80 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 68%.
The Moving Average Convergence Divergence (MACD) for ALHC just turned positive on October 02, 2026. Looking at past instances where ALHC's MACD turned positive, the stock continued to rise in 31 of 41 cases over the following month. The odds of a continued upward trend are 76%.
Following a +4.06% 3-day Advance, the price is estimated to grow further. Considering data from situations where ALHC advanced for three days, in 252 of 306 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALHC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
The Aroon Indicator for ALHC entered a downward trend on October 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 46 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 73 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: ALHC's P/B Ratio (6.203) is slightly higher than the industry average of (3.247). P/E Ratio (41.737) is within average values for comparable stocks, (139.958). ALHC's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (0.786). Dividend Yield (0.000) settles around the average of (0.009) among similar stocks. P/S Ratio (0.389) is also within normal values, averaging (0.569).
The Tickeron Price Growth Rating for this company is 94 (best 1 - 100 worst), indicating slightly worse than average price growth. ALHC’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 99 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALHC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 86, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry ManagedHealthCare
Advertisement